Hot flashes caused by cancer therapy can be prevented, treated

(Reuters Health) - Cancer patients with hot flashes related to hormone therapy should know that these uncomfortable symptoms can be managed, according to a recently published resource for patients.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news

Related Links:

CONCLUSIONS: Our study suggests that inhibition of the IGF pathway may be an effective strategy for ER-positive breast cancer therapy, even in hormone therapy-resistant cases. PMID: 30328006 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
anMeter JW, Saykin AJ, Ahles T Abstract PURPOSE: To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. METHODS: Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuro...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Oncol Source Type: research
This research article found patients who received CM were more likely to refuse additional conventional cancer treatment (surgery/chemo or radio or hormone therapy) and had higher risk of death.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news
Authors: Abstract The diagnosis of cancer in females younger than 20 years is rare, with the incidence of 17 cases per 100,000 individuals per year in the United States. Although advancements in cancer therapy have dramatically improved childhood cancer survival, gynecologists should be aware of the increased risk of adverse reproductive health effects from each type of therapy. Cancer and its treatment may have immediate or delayed adverse effects on reproductive health. Gynecologists may be consulted for the following issues: pubertal concerns; menstrual irregularities; heavy menstrual bleeding and anemia; sexu...
Source: Obstetrics and Gynecology - Category: OBGYN Tags: Obstet Gynecol Source Type: research
Authors: Abstract The diagnosis of cancer in females younger than 20 years is rare, with the incidence of 17 cases per 100,000 individuals per year in the United States. Although advancements in cancer therapy have dramatically improved childhood cancer survival, gynecologists should be aware of the increased risk of adverse reproductive health effects from each type of therapy. Cancer and its treatment may have immediate or delayed adverse effects on reproductive health. Gynecologists may be consulted for the following issues: pubertal concerns; menstrual irregularities; heavy menstrual bleeding and anemia; sexu...
Source: Obstetrics and Gynecology - Category: OBGYN Tags: Obstet Gynecol Source Type: research
People diagnosed with cancer have a multitude of treatment options, many of which are standard therapies that have been well-studied to improve their chances of surviving their disease or avoiding recurrence. But people are increasingly also folding in complementary medicine approaches — which include nutrients, herbal remedies and other so-called natural supplements — with their cancer treatment regimes. While these are not nearly as well-studied as conventional therapies like surgery, radiation and chemotherapy, many people rely on them because they believe they can improve their chances of surviving their ca...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized Cancer healthytime Source Type: news
Publication date: January 2018Source: Advances in Biological Regulation, Volume 67Author(s): Kurt Geffken, Sarah SpiegelAbstractBreast cancer affects 1 out of 8 women in the US and is the second highest cause of death from cancer for women, leading to considerable research examining the causes, progression, and treatment of breast cancer. Over the last two decades, sphingosine-1-phosphate (S1P), a potent sphingolipid metabolite, has been implicated in many processes important for breast cancer including growth, progression, transformation and metastasis, and is the focus of this review. In particular, one of the kinases th...
Source: Advances in Biological Regulation - Category: Biology Source Type: research
Conclusions: Although great progress has been made in developing value frameworks, use of those frameworks has to be refined to help patients and health care providers make informed decisions about the benefit of novel cancer therapies and to help policymakers make decisions about the societal benefit of funding those therapies. PMID: 29910659 [PubMed - in process]
Source: Current Oncology - Category: Cancer & Oncology Tags: Curr Oncol Source Type: research
Abstract Globally, breast cancer is the most common cancer and the second leading cause of cancer-related death among women. Surgery, chemotherapy, hormonal therapy, and radiotherapy are currently available treatment options for breast cancer therapy. However, chemotherapy, hormonal therapy, and radiotherapy are often associated with side effects and multidrug resistance, recurrence, and lack of treatment in metastasis are the major problems in the treatment of breast cancer. Recently, dietary phytochemicals have emerged as advantageous agents for the prevention and therapy of cancer due to their safe nature. Ella...
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
The ETS Related Gene (ERG) is dormant and non-detectable in normal prostate. Despite of significant advancements in prostate cancer treatment in recent years, hormone therapy remains the main treatment for advanced CaP. Unfortunately, late stage prostate cancers are highly prone to treatment resistance. Thus, there is an urgent need to develop effective and novel inhibitors to target CaP driver genes in the early stages of prostate tumorigenesis. ERG oncoprotein and ERG dependent pathways are promising targets for early stage cancer therapy.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Advanced (including  Drug Therapy) IV Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Health | Hormonal Therapy | Hormones